Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
Recent posts
-
Athenahealth (NASDAQ:ATHN) says it has formed a new alliance with Microsoft (NASDAQ:MSFT) to develop software to make their systems more compatible and easier for healthcare professionals to... Read more »
-
Clinical Data chief executive Drew Fromkin wasn’t blowing smoke last month when he told analysts that his firm was in talks about a potential change in control. About a month after... Read more »
-
Aveo Pharmaceuticals has beefed up its cash coffers as it heads into the home stretch of a vitally important clinical test of its lead anti-cancer drug. The Cambridge, MA-based biotech company... Read more »
-
It’s been a long time coming, but the sale of Genzyme, the Cambridge, MA-based biotech company, to pharma giant Sanofi-Aventis for $20.1 billion marks a landmark moment in the biotech industry... Read more »
-
Cellceutix, a Beverly, MA-based developer of drugs for cancer and other diseases, says that the company and its former CEO George Evans have settled a compensation dispute. The company has agreed... Read more »
-
Our immune systems churn out antibodies to fight infections, so perhaps it’s about time that some biotech companies started getting in on the action. Arsanis, co-founded late last year by successful... Read more »
-
Biogen Idec (NASDAQ:BIIB) said on February 11 that its board of directors has given the Weston, MA-based company permission to repurchase 20 million shares of its common stock to... Read more »
-
H3 Biomedicine is one of the latest experiments that hopes to revamp the way biotech drugs get developed, to save both time and money. Japanese drugmaker Eisai, which is bankrolling Cambridge,... Read more »
-
I learned a bunch during Wednesday’s Xconomy Xchange, which featured Todd Park, chief technology officer of the U.S Department of Health and Human Services, and other luminaries discussing the future of... Read more »
-
Bring an open mind and an extra business card or two. That’s what I’m planning to do as I gear up for today’s Xconony Xchange: HHS CTO Todd Park and Friends... Read more »
-
Arsanis, a mysterious biotech firm based in Lebanon, NH, has raised $9.6 million in equity financing, according to an SEC filing. Tillman Gerngross, the co-founder and CEO of the Lebanon-based... Read more »
-
Ecochlor, an Acton, MA-based provider of chlorine dioxide systems for killing off invasive species and pathogens from the large quantities of ballast water ships carry from port to port, has raised... Read more »
-
[Updated and corrected. 02/08/11 at 12 pm ET] Stern lectures about taking your heart pill as prescribed, eating right, or exercising regularly—or else—can be a real turnoff. Some people simply tune... Read more »
-
Cambridge, MA-based Stromedix is planning to begin a mid-stage trial of its lead drug in patients with a chronic lung disease called idiopathic pulmonary fibrosis before the end of June, CEO... Read more »
-
Shelton, CT-based spinal device developer Spine Wave has raised $17.6 million in debt financing, according to an SEC filing. The company said in a press release that previous investor New... Read more »
-
Pankaj Khare says he has devoted the past several years of his life and his 401K savings to a startup that he thinks will improve the way home care is delivered... Read more »
-
Ocular Therapeutix has found a new investor and a fresh round of capital to advance its hydrogel-based treatments for the eye, CEO Amar Sawhney told me yesterday. The Bedford, MA-based startup... Read more »
-
Massachusetts is expected to gain 350 jobs from Pfizer (NYSE:PFE) as the world’s largest drugmaker restructures its global research and development activities to cut $1.5 billion in spending, the... Read more »
-
Genocea Biosciences, a Cambridge, MA-based firm that specializes in rapidly discovering potential vaccines, said today it has named Chip Clark as its new chief executive. Clark, who played a key role... Read more »
-
French drug giant Sanofi-Aventis’s long-sought takeover of Cambridge, MA-based biotech company Genzyme (NASDAQ:GENZ) might happen within the next week or so, sources told The New York Times yesterday. The... Read more »
Page 4 of 55 « previous page · next page »
